Mushroom boardroom: Why some execs are using psychedelics to get through the workday
This is a preview of a story that was initially published on our sister site, WorkLife, which covers the future of the workplace.
After his father died in 2018, Paul Marlow struggled with fear, anxiety and depression. That’s when he turned to microdosing psychedelics as a remedy — and he hasn’t looked back.
Microdosing, he said, helps him focus at work. As the pandemic persists, many who are looking for a jolt of motivation, inspiration or medication are turning to microdosing — that is, ingesting small amounts of psychedelic drugs to combat mental health issues and enhance creativity, productivity and physical well-being. Read the full story on WorkLife.
More in Marketing
‘Worried about getting caught out’: Sir Martin Sorrell on why CMOs are not ready to pay for outcome-based agencies
A steady economy is emerging as the quiet counterweight to AI’s much-hyped reinvention of the agency holdco model.
‘More focused on advertising than ever before’: Nearly all of X’s top 100 advertisers returned, ads boss claims
Claim comes as X is embroiled in latest scandal that involves it’s AI chatbot Grok creating sexualized images of women and minors.
CES 2026: Agentic AI hype vs. media buyers’ pragmatism
CES 2026 was all about agentic AI, but Digiday’s Seb Joseph shares why media buyers are approaching the hype around autonomous media buying with pragmatism over urgency.